

Policy #	Policy Name	Brief Description of Policy Change
UM ONC_1194	Nexavar (sorafenib)	Annual Review
UM ONC_1219	Jevtana (cabazitaxel)	Annual Review
UM ONC_1222	Erivedge (vismodegib)	Annual Review
UM ONC_1223	Inlyta (axitinib)	Annual Review
UM ONC_1224	Kyprolis (carfilzomib)	Annual Review
UM ONC_1265	Zykadia (ceritinib)	Annual Review
UM ONC_1281	Empliciti (elotuzumab)	Annual Review
UM ONC_1335	Braftovi (encorafenib)	Annual Review
UM ONC_1344	Poteligeo (mogamulizumab-kpkc)	Annual Review
UM ONC_1384	Targretin (bexarotene)	Annual Review
UM ONC_1391	Thalomid (thalidomide)	Annual Review
UM ONC_1397	Mektovi (binimetinib)	Annual Review
UM ONC_1419	Danyelza (naxitamab-ggqk)	Annual Review
UM ONC_1454	Besremi (ropeginterferon alfa-2b-nijft)	Annual Review
UM ONC_1466	Lytgobi (futibatinib)	Annual Review
UM ONC_1467	Pedmark (sodium thiosulfate)	Annual Review
UM ONC_1487	Aphexda (motixafortide)	Annual Review
UM ONC_1488	Ojjaara (momelotinib)	Annual Review
EMOD.0001	Medical Oncology Drug List Policy	Annual Review